The following article features coverage from the Society of Gynecologic Oncology’s 50th Annual Meeting on Women’s Cancer. Click here to read more of Cancer Therapy Advisor‘s conference coverage.

Results from a retrospective study of women with stage I uterine leiomyosarcoma (LMS), a rare cancer of the uterus that develops in the smooth muscle of the uterine wall, showed no significant difference in overall survival between subgroups who did or did not receive adjuvant chemotherapy. The findings of this study were presented at the Society of Gynecologic Oncology (SGO)’s 50th Annual Meeting on Women’s Cancer.

Researchers identified 890 women with stage I uterine LMS using data from the National Cancer Database from 2010 to 2014. Demographic, as well as disease- and treatment-related characteristics were analyzed. 

Related Articles

The mean age of patients within the cohort was 54 years. Of these women, 71.2%, 21.7%, and 3.9% were classified as white, black, and Asian, respectively, with the remaining 3.1% of patients classified as other/unknown race.  

The percentages of patients who underwent nodal dissection and omentectomy during surgical staging were 38.8% and 14.6%, respectively. Disease stage was classified as stage IA (16.1%), stage IB (71.2%), or undefined stage I (12.7%).

In this cohort of patients with stage I uterine LMS, 59.3% received adjuvant chemotherapy and 40.7% did not. The researchers found that treatment with adjuvant chemotherapy was not a predictor of improved overall survival (hazard ratio, 1.04; 95% CI, 0.79-1.36, P =.787). 

Furthermore, 5-year overall survival rates with and without chemotherapy in each stage subgroup did not differ significantly:

  • Stage IA: 80.3% vs 75.5% (P =.690)
  • Stage IB: 59.1% vs 55.7% (P =.536)
  • Stage I: 60.6% vs 61.5% (P =.761)

On multivariate analysis, independent predictors of worse OS included older age, black race, higher disease substage, Charlson/Deyo Score 2, lymph vascular invasion, and positive peritoneal cytology. 

Read more of Cancer Therapy Advisor‘s coverage of SGO’s annual meeting by visiting the conference page.

Reference

  1. Richardson MT, Chan JK, Kapp DS, et al. The lack of benefit of chemotherapy for stage I uterine leiomyosarcoma patients: A retrospective analysis of 890 patients.